Actively Recruiting

Phase 1
Phase 2
Age: 6Years +
All Genders
NCT07002398

Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)

Led by VeonGen Therapeutics GmbH · Updated on 2025-12-11

15

Participants Needed

1

Research Sites

70 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a single-arm, open-label, non-randomized, single dose-escalation, first-in-human (FIH) clinical trial to evaluate the safety and preliminary efficacy of VG801 for treatment of patients with retinal dystrophy (Stargardt disease) due to biallelic ABCA4 mutations.

CONDITIONS

Official Title

Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)

Who Can Participate

Age: 6Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Written informed consent is given.
  • Participants are aged 6 years or older.
  • Clinical diagnosis of a macular lesion consistent with Stargardt disease or recessive hereditary macular dystrophy.
  • Confirmed molecular diagnosis of ABCA4 mutations (homozygotes or compound heterozygotes).
  • Poor vision in the study eye.
Not Eligible

You will not qualify if you...

  • Presence of eye conditions like uveitis, glaucoma, diabetic retinopathy, or implanted medical devices in the vitreous or subretinal space.
  • Systemic diseases preventing surgery or affecting study results.
  • History of intraocular surgery within the last 6 months.
  • Previous participation in a gene therapy trial.
  • Participation in another clinical trial involving investigational drugs or devices within the last 6 months.
  • Other eye diseases that could impact study outcomes, such as ocular opacities, advanced cataracts, or amblyopia.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai General Hospital

Shanghai, Shanghai Municipality, China, 200080

Actively Recruiting

Loading map...

Research Team

R

Research Coordinator

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease) | DecenTrialz